Market Cap | 57.73M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -15.97M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -66.00% |
Sales | 12.32k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -77.00% |
Recommedations | - | Quick Ratio | 0.42 | Shares Outstanding | 20.91M | 52W Low Chg | 6.00% |
Insider Own | 33.64% | ROA | -84.64% | Shares Float | 11.99M | Beta | 0.33 |
Inst Own | 17.58% | ROE | - | Shares Shorted/Prior | 41.29K/58.63K | Price | 3.00 |
Gross Margin | 97.63% | Profit Margin | - | Avg. Volume | 532,908 | Target Price | - |
Oper. Margin | -9,671.16% | Earnings Date | - | Volume | 162,581 | Change | -7.38% |
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Spenlehauer Gilles | Director Director | Dec 14 | Buy | 3.77 | 904 | 3,408 | 5,381 | 12/18/23 |
Frisch Scott M. | Director Director | Dec 14 | Buy | 3.77 | 904 | 3,408 | 5,381 | 12/18/23 |
Sturgeon Patrick A | Director Director | Dec 14 | Buy | 3.77 | 1,130 | 4,260 | 6,727 | 12/18/23 |
Gregory Kathryn | Director Director | Dec 14 | Buy | 3.77 | 1,130 | 4,260 | 6,727 | 12/18/23 |
Anderson David W | Director Director | Dec 14 | Buy | 3.77 | 1,130 | 4,260 | 6,727 | 12/18/23 |
Upton Richard A | Director Director | Dec 12 | Buy | 3.49 | 4,400 | 15,356 | 4,400 | 12/13/23 |
Sturgeon Patrick A | Director Director | Dec 11 | Buy | 4.2 | 3,261 | 13,696 | 5,597 | 12/13/23 |
Frisch Scott M. | Director Director | Dec 11 | Buy | 4.2 | 2,608 | 10,954 | 4,477 | 12/13/23 |
Spenlehauer Gilles | Director Director | Dec 11 | Buy | 4.2 | 2,608 | 10,954 | 4,477 | 12/13/23 |
Gregory Kathryn | Director Director | Dec 11 | Buy | 4.2 | 3,261 | 13,696 | 5,597 | 12/13/23 |
Anderson David W | Director Director | Dec 11 | Buy | 4.2 | 3,261 | 13,696 | 5,597 | 12/13/23 |
Anderson David W | Director Director | Dec 04 | Buy | 3.07 | 2,336 | 7,172 | 2,336 | 12/08/23 |
Sturgeon Patrick A | Director Director | Dec 04 | Buy | 3.07 | 2,336 | 7,172 | 2,336 | 12/08/23 |
Gregory Kathryn | Director Director | Dec 04 | Buy | 3.07 | 2,336 | 7,172 | 2,336 | 12/08/23 |
Spenlehauer Gilles | Director Director | Dec 04 | Buy | 3.07 | 1,869 | 5,738 | 1,869 | 12/08/23 |
Frisch Scott M. | Director Director | Dec 04 | Buy | 3.07 | 1,869 | 5,738 | 1,869 | 12/08/23 |
Shukla Rajiv | Chairman and CEO Chairman and CEO | Nov 28 | Buy | 2.75 | 13,617 | 37,447 | 34,179 | 12/04/23 |
Cassaday Bryan J. | Chief Financial Offi.. Chief Financial Officer | Nov 28 | Buy | 2.85 | 1,500 | 4,275 | 1,500 | 11/30/23 |
Shukla Rajiv | Chairman and CEO Chairman and CEO | Nov 22 | Buy | 2.9 | 6,000 | 17,400 | 20,562 | 11/28/23 |
Shukla Rajiv | Chairman and CEO Chairman and CEO | Nov 17 | Buy | 2.6 | 5,950 | 15,470 | 14,562 | 11/21/23 |
Hubbell Randolph W | President and CEO President and CEO | Aug 17 | Buy | 3.6 | 2,750 | 9,900 | 2,750 | 08/30/23 |